MARKET

EXEL

EXEL

Exelixis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.82
-0.62
-3.03%
After Hours: 20.20 +0.38 +1.92% 19:54 01/17 EST
OPEN
20.57
PREV CLOSE
20.44
HIGH
20.57
LOW
19.78
VOLUME
2.53M
TURNOVER
--
52 WEEK HIGH
25.31
52 WEEK LOW
15.02
MARKET CAP
6.02B
P/E (TTM)
10.13
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EXEL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 13 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EXEL News

  • GILD or EXEL: Which Is the Better Value Stock Right Now?
  • Zacks.1d ago
  • 5 Mid-Cap Stocks You'll Want to Own in 2020
  • MotleyFool.com.3d ago
  • Exelixis Option Alert: Fri $19 Calls Sweep (20) near the Ask: 1063 @ $0.7 vs 2183 OI; Earnings 2/11 After Close [est] Ref=$19.31
  • Benzinga.4d ago
  • Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio?
  • Simply Wall St..4d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About EXEL

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.
More

Webull offers Exelixis, Inc. (EXEL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.